Chronic Immune Response Dysregulation in MDS Pathogenesis

Overview

Journal Blood

Publisher Elsevier

Specialty Hematology

Date 2018 Aug 15

PMID 30104218

Citations 116

Authors

Laura Barreyro

Timothy M Chlon

Daniel T Starczynowski

Affiliations

Soon will be listed here.

Abstract

Chronic innate immune signaling in hematopoietic cells is widely described in myelodysplastic syndromes (MDS), and innate immune pathway activation, predominantly via pattern recognition receptors, increases the risk of developing MDS. An inflammatory component to MDS has been reported for many years, but only recently has evidence supported a more direct role of chronic innate immune signaling and associated inflammatory pathways in the pathogenesis of MDS. Here we review recent findings and discuss relevant questions related to chronic immune response dysregulation in MDS.

Citing Articles

The Emerging Role of CD8 T Cells in Shaping Treatment Outcomes of Patients with MDS and AML.

Tasis A, Spyropoulos T, Mitroulis I Cancers (Basel). 2025; 17(5).

PMID: 40075597 PMC: 11898900. DOI: 10.3390/cancers17050749.

The rewired immune microenvironment in leukemia.

Ciantra Z, Paraskevopoulou V, Aifantis I Nat Immunol. 2025; 26(3):351-365.

PMID: 40021898 DOI: 10.1038/s41590-025-02096-9.

Unveiling Myelodysplastic Syndromes: Exploring Pathogenic Mechanisms and Therapeutic Advances.

Thalambedu N, Mohan Lal B, Harbaugh B, Alapat D, Gaddam M, Gentille Sanchez C Cancers (Basel). 2025; 17(3).

PMID: 39941875 PMC: 11816122. DOI: 10.3390/cancers17030508.

Emerging interleukin-1 receptor-associated kinase 4 (IRAK4) inhibitors or degraders as therapeutic agents for autoimmune diseases and cancer.

Feng Y, Chen C, Shao A, Wu L, Hu H, Zhang T Acta Pharm Sin B. 2025; 14(12):5091-5105.

PMID: 39807338 PMC: 11725142. DOI: 10.1016/j.apsb.2024.09.008.

Inflammation and Related Signaling Pathways in Acute Myeloid Leukemia.

Naji N, Sathish M, Karantanos T Cancers (Basel). 2024; 16(23).

PMID: 39682161 PMC: 11640130. DOI: 10.3390/cancers16233974.

References

De Luca K, Frances-Duvert V, Asensio M, Ihsani R, Debien E, Taillardet M . The TLR1/2 agonist PAM(3)CSK(4) instructs commitment of human hematopoietic stem cells to a myeloid cell fate. Leukemia. 2009; 23(11):2063-74. DOI: 10.1038/leu.2009.155. View

Varney M, Melgar K, Niederkorn M, Smith M, Barreyro L, Starczynowski D . Deconstructing innate immune signaling in myelodysplastic syndromes. Exp Hematol. 2015; 43(8):587-598. PMC: 4635673. DOI: 10.1016/j.exphem.2015.05.016. View

Benz C, Copley M, Kent D, Wohrer S, Cortes A, Aghaeepour N . Hematopoietic stem cell subtypes expand differentially during development and display distinct lymphopoietic programs. Cell Stem Cell. 2012; 10(3):273-83. DOI: 10.1016/j.stem.2012.02.007. View

Chen S, Sheng C, Liu D, Yao C, Gao S, Song L . Enhancer of zeste homolog 2 is a negative regulator of mitochondria-mediated innate immune responses. J Immunol. 2013; 191(5):2614-23. DOI: 10.4049/jimmunol.1203143. View

Keerthivasan G, Mei Y, Zhao B, Zhang L, Harris C, Gao J . Aberrant overexpression of CD14 on granulocytes sensitizes the innate immune response in mDia1 heterozygous del(5q) MDS. Blood. 2014; 124(5):780-90. PMC: 4118486. DOI: 10.1182/blood-2014-01-552463. View

Ma S, Wan X, Deng Z, Shi L, Hao C, Zhou Z . Epigenetic regulator CXXC5 recruits DNA demethylase Tet2 to regulate TLR7/9-elicited IFN response in pDCs. J Exp Med. 2017; 214(5):1471-1491. PMC: 5413332. DOI: 10.1084/jem.20161149. View

Chen X, Deng H, Churchill M, Luchsinger L, Du X, Chu T . Bone Marrow Myeloid Cells Regulate Myeloid-Biased Hematopoietic Stem Cells via a Histamine-Dependent Feedback Loop. Cell Stem Cell. 2017; 21(6):747-760.e7. PMC: 5975960. DOI: 10.1016/j.stem.2017.11.003. View

Kornblau S, McCue D, Singh N, Chen W, Estrov Z, Coombes K . Recurrent expression signatures of cytokines and chemokines are present and are independently prognostic in acute myelogenous leukemia and myelodysplasia. Blood. 2010; 116(20):4251-61. PMC: 4081283. DOI: 10.1182/blood-2010-01-262071. View

Olsnes Kittang A, Kordasti S, Sand K, Costantini B, Kramer A, Perezabellan P . Expansion of myeloid derived suppressor cells correlates with number of T regulatory cells and disease progression in myelodysplastic syndrome. Oncoimmunology. 2016; 5(2):e1062208. PMC: 4801428. DOI: 10.1080/2162402X.2015.1062208. View

10.

Zhang H, Hu H, Greeley N, Jin J, Matthews A, Ohashi E . STAT3 restrains RANK- and TLR4-mediated signalling by suppressing expression of the E2 ubiquitin-conjugating enzyme Ubc13. Nat Commun. 2014; 5:5798. PMC: 4270087. DOI: 10.1038/ncomms6798. View

11.

Saft L, Bjorklund E, Berg E, Hellstrom-Lindberg E, Porwit A . Bone marrow dendritic cells are reduced in patients with high-risk myelodysplastic syndromes. Leuk Res. 2012; 37(3):266-73. DOI: 10.1016/j.leukres.2012.10.010. View

12.

Zhao Y, Wu D, Fei C, Guo J, Gu S, Zhu Y . Down-regulation of Dicer1 promotes cellular senescence and decreases the differentiation and stem cell-supporting capacities of mesenchymal stromal cells in patients with myelodysplastic syndrome. Haematologica. 2014; 100(2):194-204. PMC: 4803146. DOI: 10.3324/haematol.2014.109769. View

13.

Hajjar A, Ernst R, Tsai J, Wilson C, Miller S . Human Toll-like receptor 4 recognizes host-specific LPS modifications. Nat Immunol. 2002; 3(4):354-9. DOI: 10.1038/ni777. View

14.

Moudra A, Hubackova S, Machalova V, Vancurova M, Bartek J, Reinis M . Dynamic alterations of bone marrow cytokine landscape of myelodysplastic syndromes patients treated with 5-azacytidine. Oncoimmunology. 2016; 5(10):e1183860. PMC: 5087287. DOI: 10.1080/2162402X.2016.1183860. View

15.

Fuster J, MacLauchlan S, Zuriaga M, Polackal M, Ostriker A, Chakraborty R . Clonal hematopoiesis associated with TET2 deficiency accelerates atherosclerosis development in mice. Science. 2017; 355(6327):842-847. PMC: 5542057. DOI: 10.1126/science.aag1381. View

16.

Santamaria C, Muntion S, Roson B, Blanco B, Lopez-Villar O, Carrancio S . Impaired expression of DICER, DROSHA, SBDS and some microRNAs in mesenchymal stromal cells from myelodysplastic syndrome patients. Haematologica. 2012; 97(8):1218-24. PMC: 3409820. DOI: 10.3324/haematol.2011.054437. View

17.

Ehrchen J, Sunderkotter C, Foell D, Vogl T, Roth J . The endogenous Toll-like receptor 4 agonist S100A8/S100A9 (calprotectin) as innate amplifier of infection, autoimmunity, and cancer. J Leukoc Biol. 2009; 86(3):557-66. DOI: 10.1189/jlb.1008647. View

18.

Wiseman H, Halliwell B . Damage to DNA by reactive oxygen and nitrogen species: role in inflammatory disease and progression to cancer. Biochem J. 1996; 313 ( Pt 1):17-29. PMC: 1216878. DOI: 10.1042/bj3130017. View

19.

Neele A, de Winther M . Repressing the repressor: Ezh2 mediates macrophage activation. J Exp Med. 2018; 215(5):1269-1271. PMC: 5940273. DOI: 10.1084/jem.20180479. View

20.

Kotsianidis I, Bouchliou I, Nakou E, Spanoudakis E, Margaritis D, Christophoridou A . Kinetics, function and bone marrow trafficking of CD4+CD25+FOXP3+ regulatory T cells in myelodysplastic syndromes (MDS). Leukemia. 2008; 23(3):510-8. DOI: 10.1038/leu.2008.333. View